کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3391400 | 1221043 | 2013 | 9 صفحه PDF | دانلود رایگان |

• System biology approaches toward understanding immune dysfunction in HIV infection.
• Transcriptional programs regulating anergy and cell survival in chronic HIV infection.
• PD-1 expression correlates with both functional and dysfunctional immune responses.
• Blocking PD-1 and other immune checkpoints in HIV potentiates CD8 effector function.
• New computational methods are needed to model regulation of transcriptional networks.
In the majority of HIV-1 infected individuals, the adaptive immune response drives virus escape resulting in persistent viremia and a lack of immune-mediated control. The expression of negative regulatory molecules such as PD-1 during chronic HIV infection provides a useful marker to differentiate functional memory T cell subsets and the frequency of T cells with an exhausted phenotype. In addition, cell-based measurements of virus persistence equate with activation markers and the frequency of CD4 T cells expressing PD-1. High-level expression of PD-1 and its ligands PD-L1 and PD-L2 are found on hematopoietic and non-hematopoietic cells, and are upregulated by chronic antigen stimulation, Type 1 and Type II interferons (IFNs), and homeostatic cytokines. In HIV infected subjects, PD-1 levels on CD4 and CD8 T cells continue to remain high following combination anti-retroviral therapy (cART). System biology approaches have begun to elucidate signal transduction pathways regulated by PD-1 expression in CD4 and CD8 T cell subsets that become dysfunctional through chronic TCR activation and PD-1 signaling. In this review, we summarize our current understanding of transcriptional signatures and signal transduction pathways associated with immune exhaustion with a focus on recent work in our laboratory characterizing the role of PD-1 in T cell dysfunction and HIV pathogenesis. We also highlight the therapeutic potential of blocking PD-1–PD-L1 and other immune checkpoints for activating potent cellular immune responses against chronic viral infections and cancer.
Journal: Seminars in Immunology - Volume 25, Issue 3, 31 October 2013, Pages 219–227